Lenalidomide mediates the ubiquitination and degradation of Ikaros family zinc finger
protein 1 (IKZF1), IKZF3, and casein kinase 1α (CK1α) by facilitating their interaction with …

Simple Summary In the last decade, proteasome inhibitors (PIs) have become a standard for
the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs …

Introduction: Significant advances have been made during the last two decades in terms of
new therapeutic options but also of innovative approaches to diagnosis and management of …

The thalidomide analogue lenalidomide (Len) is a clinical therapeutic that alters the
substrate engagement of cereblon (CRBN), a substrate receptor for the CRL4 E3 ubiquitin …

Multiple myeloma cells aberrantly express surface antigens compared with normal plasma
cells. Among others, CD56 is present at variable levels in approximately 70% of patients …

Autophagy can protect stressed cancer cell by degradation of damaged proteins and
organelles. However, the regulatory mechanisms behind this cellular process remain …

Recent years have witnessed a dramatic increase in the number of therapeutic options
available for the treatment of multiple myeloma (MM)-from immunomodulating agents to …

Cytogenetic/molecular heterogeneity is the hallmark of multiple myeloma (MM). However,
we recently showed that the serine/threonine kinase PDPK 1 and its substrate RPS 6 KA 3 …

BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring
BRAFV600E mutant. Despite the benefit of vemurafenib therapy, acquired resistance during …

Long noncoding RNAs (lncRNAs) encompass short open reading frames (sORFs) that can
be translated into small peptides. Here, we investigated the encoding potential of lncRNA …